Pfizer (PFE) Deferred Taxes (2009 - 2026)

Pfizer (PFE) has reported Deferred Taxes for 18 consecutive years, with -$1.3 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Deferred Taxes fell 385.29% year-over-year to -$1.3 billion in Q2 2026; TTM through Jun 2026 was -$2.5 billion, a 26.11% increase from a year earlier, with the FY2025 full-year figure at -$2.1 billion, down 1.47% from the prior year.
• Deferred Taxes was -$1.3 billion for Q2 2026 at Pfizer, down from -$12.0 million in the prior quarter.
• Over five years, Deferred Taxes peaked at -$12.0 million in Q1 2026 and troughed at -$2.3 billion in Q2 2022.
• A 5-year average of -$941.8 million and a median of -$774.0 million in 2024 frame the typical range for Deferred Taxes.
• Across the five-year window, Deferred Taxes slumped 1627.27% in 2022 and soared 98.19% in 2026, its largest moves.
• Over 5 years, Deferred Taxes stood at -$1.1 billion in 2022, then slumped by 62.98% to -$1.9 billion in 2023, then advanced by 8.18% to -$1.7 billion in 2024, then soared by 74.62% to -$433.0 million in 2025, then slumped by 204.85% to -$1.3 billion in 2026.
• The last three Deferred Taxes figures came in at -$1.3 billion (Q2 2026), -$12.0 million (Q1 2026), and -$433.0 million (Q4 2025), per Business Quant data.